Autres langues Viking Therapeutics, Inc.

Actions

VKTX

US92686J1060

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Pré-ouverture 14:39:51
75,42 ^USD	+1,49 %		76,75	+1,76 %

24/04	Viking Therapeutics aggrave sa perte au premier trimestre ; les actions chutent après les heures de bureau	MT
24/04	Transcript : Viking Therapeutics, Inc., Q1 2024 Earnings Call, Apr 24, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	25/04
Viking Therapeutics Q1 Loss Widens; Shares Fall After Hours	24/04
Viking Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
6 Stocks Positioned to Soar as Investors Focus on MASH	22/04
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024	17/04
Health Care Falls as Risk Aversion Weighs on Obesity Drug Makers -- Health Care Roundup	12/04
Health Care Down on Flight From Risk -- Health Care Roundup	02/04
Health Care Down as Obesity-Drug Optimism Fades -- Health Care Roundup	01/04
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	26/03
Sector Update: Health Care Stocks Rise Tuesday Afternoon	26/03
Sector Update: Health Care	26/03
Viking Therapeutics Share Rise After Reporting 'Positive Results' in Study of Potential Obesity Drug	26/03
Sector Update: Health Care Stocks Steady Premarket Tuesday	26/03
Sector Update: Health Care	26/03
Viking Therapeutics Reports 'Positive Results' in Study of Potential Obesity Drug; Shares Jump	26/03
PE firm Olympus to sell 9.8% stake in India's Aster DM Healthcare for up to $234.5 million, term sheet shows	26/03
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735	26/03
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735	26/03
Viking Therapeutics Announces $632.5 Million Public Offering Of Common Stock	13/03
Viking Therapeutics Raises $632.5 Million Via Common Stock Offering	04/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Viking Therapeutics, Inc.

Actions

VKTX

US92686J1060

Autres langues

Filtres